Semaglutide is a long-acting GLP-1 receptor agonist with 94% structural homology to native GLP-1(7-37). It incorporates three key modifications: an Aib (\u03b1-aminoisobutyric acid) substitution at position 8 for DPP-4 resistance, an arginine to alanine substitution at position 34, and an acylated C18 fatty diacid chain at lysine 26 that enables high-affinity albumin binding, extending its plasma half-life to approximately 7 days. Semaglutide activates the GLP-1R on pancreatic beta cells, hypothalamic neurons, and gastrointestinal vagal afferents, producing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and centrally-mediated appetite reduction. Landmark clinical research programs (SUSTAIN and STEP) have demonstrated significant improvements in glycemic control and body weight reduction. Research applications extend to cardiovascular risk reduction studies, non-alcoholic steatohepatitis (NASH) models, neurodegenerative disease research (including Alzheimer’s and Parkinson’s models), and kidney disease progression studies. The 2 mg format supports standard-duration research protocols.<\/p>\n","protected":false},"excerpt":{"rendered":"
Semaglutide is a long-acting GLP-1 receptor agonist with 94% structural homology to native GLP-1(7-37). It incorporates three key modifications: an Aib (\u03b1-aminoisobutyric acid) substitution at position 8 for DPP-4 resistance, an arginine to alanine substitution at position 34, and an acylated C18 fatty diacid chain at lysine 26 that enables high-affinity albumin binding, extending its […]<\/p>\n","protected":false},"featured_media":79,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[17],"product_tag":[],"class_list":["post-80","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n